T1	Participants 112 140	HER2-positive breast cancer:
T2	Participants 238 299	patients who will benefit from targeted anticancer therapies.
T3	Participants 385 479	455 women with invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer
T4	Participants 828 861	assessed in a subset of patients.
T5	Participants 870 916	Eighty-six patients underwent (18)F-FDG PET/CT
